AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29650060
Drug: Pre-treatment gastrostomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment gastrostomy tube feeding
Trial: 29650060
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding plus as-required nasogastric tube feeding
Trial: 28629132
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (2800 IU daily for eight weeks)
Trial: 19099850
Drug: Pulmonary surfactant
RxNorm normalized name: Pulmonary surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary surfactant (PS) treatment in preterm infants (n=28)
Trial: 19099850
Drug: Pulmonary surfactant
RxNorm normalized name: Pulmonary surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulmonary surfactant (PS) treatment in term and late-preterm infants (n=8)
Trial: 12451480
Drug: Rubitecan 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rubitecan 1.5 mg/m(2) per day orally
Trial: 8813496
Drug: Oral methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral methylprednisolone (100 mg per day initially, dosage reduction every 3 days; n = 15)
Trial: 8813496
Drug: Thiamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiamine (100 mg per day; n = 33)
Trial: 1827103
Drug: Clarithromycin 250
RxNorm normalized name: clarithromycin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg orally (500 mg for lung tissue), administered every 12 h for three days.
Trial: 1827103
Drug: Roxithromycin 150
RxNorm normalized name: roxithromycin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roxithromycin 150 mg orally, administered every 12 h for three days.
Trial: 31399091
Drug: CHF6001 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 800 μg
Trial: 31399091
Drug: CHF6001 1600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHF6001 1600 μg
Trial: 26712982
Drug: Gabapentin 600
RxNorm normalized name: gabapentin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 600 mg capsule 1 hour before surgery
Trial: 21943111
Drug: Restrictive fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Restrictive fluid strategy (4 ml/kg/hour of Ringer's lactate solution)
Trial: 21943111
Drug: Conventional fluid
RxNorm normalized name: amniotic fluid (bovine)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional fluid strategy (12 ml/kg/hour of Ringer's lactate solution)
Trial: 18588512
Drug: ACEi (angiotensin‐converting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEi (angiotensin‐converting enzyme inhibitors)
Trial: 18588512
Drug: ARBs (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARBs (angiotensin II receptor blockers)
Trial: 16515395
Drug: HTT-blocking antidepressants
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HTT-blocking antidepressants (SSRIs, TCAs)
Trial: 15260082
Drug: Ketamine (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.3 mg/kg/hr) and Propofol (initial rate of 10 mg/kg/hr)
Trial: 15260082
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) and Propofol (initial rate of 10 mg/kg/hr)
Trial: 11729708
Drug: Infloran Berna
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infloran Berna (10^9 Lactobacillus acidophilus and 10^9 Bifidobacterium infantis, one capsule tid for 4 days)
Trial: 11729708
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (parenteral rehydration only)
Trial: 8219661
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acid based lipid emulsion (100 ml/day with 2.1 g eicosapentaenoic (EPA) and 21 g docosahexaenoic acid (DHA))
Trial: 8219661
Drug: Conventional n-6
RxNorm normalized name: 18:3 (n-6)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional n-6 lipid emulsion (EPA + DHA < 0.1 g/100 ml)
Trial: 2887189
Drug: epanolol 400
RxNorm normalized name: epanolol
DrugBank: Epanolol (DB13757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol 400 mg
Trial: 2887189
Drug: epanolol 200
RxNorm normalized name: epanolol
DrugBank: Epanolol (DB13757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol 200 mg
Trial: 2887189
Drug: epanolol 400
RxNorm normalized name: epanolol
DrugBank: Epanolol (DB13757)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: epanolol 400 mg and atenolol 100 mg
Trial: 27072143
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release morphine (IRM)
Trial: 24939433
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg isoflavones/day (supplements)
Trial: 24939433
Drug: 48 mg
RxNorm normalized name: betaine 648 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 48 mg isoflavones/day (soy foods)
Trial: 23933107
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 12 sessions
Trial: 23933107
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (ACT) for 12 sessions
Trial: 23933107
Drug: Overall predictor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall predictor of treatment outcome
Trial: 16619561
Drug: sEGFR levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEGFR levels below 45 ng/mL
Trial: 16619561
Drug: sEGFR levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEGFR levels below 45 ng/mL and elevated serum HER‐2/neu ECD (>15 ng/mL)
Trial: 16619561
Drug: sEGFR levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEGFR levels below 45 ng/mL in estrogen receptor-positive tumors
Trial: 16619561
Drug: sEGFR levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sEGFR levels below 45 ng/mL in estrogen receptor-positive tumors with elevated HER‐2/neu ECD
Trial: 2017337
Drug: Regimen A:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen A: vancomycin 250 mg, tobramycin 75 mg, colistin 1 million IU, nystatin
Trial: 2017337
Drug: Regimen B:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regimen B: vancomycin 125 mg, tobramycin 75 mg, colistin 1 million IU, nystatin
Trial: 618711
Drug: Stroma-free hemoglobin
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroma-free hemoglobin (SFH) infusion (250 ml administered slowly intravenously)
Trial: 618711
Drug: Stroma-free hemoglobin
RxNorm normalized name: acid red 337 free acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stroma-free hemoglobin (SFH) infusion
Trial: 618711
Drug: Serum albumin
RxNorm normalized name: Serum albumin
DrugBank: Albumin human (DB00062)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum albumin (250 ml administered to control group)
Trial: 28765029
Drug: 2-stage surgery
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2-stage surgery (sequential cervical and thoracic decompressions)
Trial: 14723482
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine administered at 9-10 months
Trial: 14723482
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine administered at 15-18 months
Trial: 9469983
Drug: Potato +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato + 100 g butter
Trial: 9469983
Drug: Potato +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato + 40 g olive oil
Trial: 9469983
Drug: Potato +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato + 50 g butter
Trial: 9469983
Drug: Potato +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potato + 80 g olive oil
Trial: 7893263
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg vitamin B6 (pyridoxine hydrochloride)
Trial: 2516308
Drug: Metronidazole (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (6 g total, intraoral application six times)
Trial: 2516308
Drug: Irradiation twice
RxNorm normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irradiation twice a day
Trial: 28397104
Drug: Omeprazole (OME)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OME) 40 mg administered postoperatively
Trial: 23843495
Drug: G‐CHOP (obinutuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CHOP (obinutuzumab plus cyclophosphamide, doxorubicin, vincristine, and prednisone)
Trial: 23843495
Drug: G‐FC (obinutuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐FC (obinutuzumab plus fludarabine and cyclophosphamide)
Trial: 23843495
Drug: G‐CHOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CHOP
Trial: 23843495
Drug: G‐FC
RxNorm normalized name: Gemcitabine and Fluorouracil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐FC
Trial: 18991471
Drug: Saline 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 100 mL
Trial: 15845796
Drug: Gadobenate dimeglumine
RxNorm normalized name: Gadobenate Dimeglumine
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadobenate dimeglumine at doses of 0.05, 0.10, or 0.20 mmol/kg
Trial: 15845796
Drug: Gadopentetate dimeglumine
RxNorm normalized name: Gadopentetate Dimeglumine
DrugBank: Gadopentetic acid (DB00789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadopentetate dimeglumine at a dose of 0.10 mmol/kg
Trial: 1744962
Drug: HA-1A monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HA-1A monoclonal antibody
Trial: 31614361
Drug: 2 doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of fosfomycin (group A)
Trial: 31614361
Drug: 3 doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 doses of fosfomycin (group B)
Trial: 26649536
Drug: 8-week Internet-delivered
RxNorm normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 8-week Internet-delivered acceptance-based cognitive behavioral therapy (ACT)
Trial: 17971948
Drug: Chinese herbs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbs treatment, administered as customized soups, taken twice daily for one week.
Trial: 17971948
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine treatment (WM), details not specified.
Trial: 3092655
Drug: Enprostil 35
RxNorm normalized name: enprostil
DrugBank: Enprostil (DB13824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enprostil 35 micrograms administered twenty minutes before each dose of aspirin
Trial: 3092655
Drug: Aspirin 600
RxNorm normalized name: aspirin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 600 mg given over 48 hours
Trial: 18757653
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: Monthly replacement of the ring with no ring-free days
Trial: 18757653
Drug: Group 2:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 2: Monthly replacement of the ring with a 4-day hormone-free interval if breakthrough bleeding/spotting occurred for 5 days or more
Trial: 18757653
Drug: 4-day hormone-free
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4-day hormone-free interval
Trial: 10440160
Drug: Prolonged heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged heparin infusion (12 to 24 h) followed by sheath removal (Group 1)
Trial: 10440160
Drug: Early removal
RxNorm normalized name: Super Spot Remover
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early removal of sheaths followed by reinstitution of heparin infusion for 12 to 18 h (Group 2)
Trial: 10440160
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further heparin after intervention with early sheath removal (Group 3)
Trial: 7759460
Drug: Albuterol powder
RxNorm normalized name: albuterol Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol powder 200 micrograms
Trial: 7759460
Drug: Albuterol aerosol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol aerosol 180 micrograms
Trial: 2334618
Drug: Continuous i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous i.v. infusion of morphine (mean 73.6 mg)
Trial: 2334618
Drug: Continuous extradural
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous extradural infusion of 0.25% bupivacaine (mean 192 mg)
Trial: 26870683
Drug: GABA-enriched white
RxNorm normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GABA-enriched white rice (11.2 mg GABA/100 g of rice)
Trial: 26870683
Drug: Placebo rice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo rice (2.7 mg GABA/100 g of rice)
Trial: 25033925
Drug: 50,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 IU Vitamin D3 at monthly intervals
Trial: 21577132
Drug: Iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 400 at 3 mL/s (IDR = 1.2 gI/s)
Trial: 21577132
Drug: Iomeprol 400
RxNorm normalized name: Iomeprol 400 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 400 at 4 mL/s (IDR = 1.6 gI/s)
Trial: 21577132
Drug: Iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 300 at 5.4 mL/s (IDR = 1.6 gI/s)
Trial: 21577132
Drug: Iomeprol 300
RxNorm normalized name: Iomeprol 300 MG/1 ML Injection Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iomeprol 300 at 4 mL/s (IDR = 1.2 gI/s)
Trial: 20399996
Drug: Dispersible tablet
RxNorm normalized name: Aspirin 75 mg orodispersible tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dispersible tablet formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Trial: 20399996
Drug: Branded capsule
RxNorm normalized name: Eagle Brand Medicated Oil
DrugBank: Eucalyptus oil (DB11114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branded capsule formulation of ampicillin/probenecid (1500 mg total; 250 mg each containing ampicillin 194.5 mg and probenecid 55.5 mg)
Trial: 18061070
Drug: GTN treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GTN treatment for 48 hours
Trial: 9806691
Drug: Intraarticular triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarticular triamcinolone acetonide 10 mg in isotonic saline 20 mL
Trial: 9806691
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline 20 mL
Trial: 337493
Drug: Methylphenidate (larger
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (larger doses)
Trial: 30782672
Drug: Group Metacognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Metacognitive Grief Therapy (MCGT)
Trial: 27394187
Drug: Regular therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular therapy alone (C group)
Trial: 21729732
Drug: PCV-7 vaccine
RxNorm normalized name: PCV
DrugBank: Penciclovir (DB00299)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PCV-7 vaccine
Trial: 22916192
Drug: Serogroup C
RxNorm normalized name: Neisseria meningitidis serogroup C Ag
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serogroup C meningococcal conjugate vaccine
Trial: 2122630
Drug: L-carnitine 10
RxNorm normalized name: coenzyme Q10/L-carnitine 100 mg-20 mg ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine 10 mg/kg (n = 6)
Trial: 366182
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg intravenous indomethacin
Trial: 366182
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg intravenous riboflavin (placebo)
Trial: 23312888
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus paclitaxel (10 mg/kg on days 1 and 15; 90 mg/m² on days 1, 8, and 15, every 4 weeks)
Trial: 23312888
Drug: Bevacizumab plus
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab plus capecitabine (15 mg/kg on day 1; 1000 mg/m² twice daily on days 1-14, every 3 weeks)
Trial: 15722700
Drug: Intensive telephone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive telephone follow-up (12 weekly phone calls)
Trial: 12823593
Drug: 1.0 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 microg/kg peginterferon‐alpha‐2b twice weekly for 4 weeks
Trial: 12823593
Drug: 1.0 microg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 microg/kg peginterferon‐alpha‐2b once weekly for 4 weeks
Trial: 10910848
Drug: droperidol (0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol (0.625 mg)
Trial: 8237746
Drug: Subcutaneous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous heparin (12,500 units subcutaneously every 12 hours for three doses after sheath removal)
Trial: 8237746
Drug: Intravenous heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous heparin (1000 units/hour for 12 to 18 hours)
Trial: 27149489
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg bolus before sedation, continuous infusion at 2 mg/kg/h during sedation)
Trial: 27149489
Drug: Control (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (normal saline, same bolus and infusion volumes as lidocaine)
Trial: 25304475
Drug: Continuous right
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous right thoracic paravertebral block with 10-mL bolus of 0.2% ropivacaine followed by continuous infusion of 6 mL/h for 24 hours (PVB group)
Trial: 25304475
Drug: Saline administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline administered through the same catheter scheme (control group)
Trial: 22860302
Drug: Propofol (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1 mg x kg(‐1) on induction)
Trial: 19545320
Drug: Instructions associated
RxNorm normalized name: HEPATITIS ASSOCIATED ANTIBODY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructions associated with the home use of a disclosing agent (1% neutral red)
Trial: 19545320
Drug: Oral and
RxNorm normalized name: Tridate, oral and rectal kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral and denture hygiene instructions
Trial: 18467544
Drug: Nutrient supplement
RxNorm normalized name: Votrient
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Nutrient supplement (protein, carbohydrate, calcium, and vitamin D)
Trial: 12633127
Drug: Integrated family
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated family and individual therapy (IFIT)
Trial: 8550792
Drug: Growth Hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth Hormone (GH) 2 IU/m2
Trial: 8550792
Drug: Insulin-like Growth
RxNorm normalized name: Insulin-like growth factor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin-like Growth Factor I (IGF‐I) 80 micrograms/kg
Trial: 1801154
Drug: Amocarzine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amocarzine 3 mg/kg oral dose twice daily for three days (fed patients)
Trial: 1801154
Drug: Amocarzine 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amocarzine 3 mg/kg oral dose twice daily for three days (fasting patients)
Trial: 29874535
Drug: Mifepristone pretreatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone pretreatment (200 mg orally) followed by misoprostol (800 μg vaginally)
Trial: 29874535
Drug: Misoprostol alone
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Misoprostol alone (800 μg vaginally)
Trial: 17385022
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (HC)
Trial: 17385022
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone (DEX)
Trial: 17385022
Drug: Intravenous methylprednisolone
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous methylprednisolone (MPL)
Trial: 17385022
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral prednisolone (PNL)
Trial: 1284163
Drug: gallopamil SR
RxNorm normalized name: gallopamil
DrugBank: Gallopamil (DB12923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gallopamil SR 100 mg twice a day